Biotech

An Australian biotech minnow wants to become the first company globally to register an over-the-counter cannabidiol product for sleep disorders.

Brisbane-based AdvanCell raised $178 million in one of the biggest funding rounds of 2025 so far. It's good news for an overlooked corner of the startup sector.

Shares in the biotech giant plunged today after a sharp sales decline in its immunisation business in the US, where vaccine-sceptic Robert F Kennedy Jr is set to become health secretary.

In 2018, Archer pivoted from resource exploration to quantum computing. Now, six months after its CEO exited, it is at another inflection point.

Main Sequence has recruited three healthcare specialists and hopes to expand investments across therapeutics, diagnostics, devices and digital health, with a particular focus on women's health.

Silicon Valley venture capitalist Reed Jobs sees parallels between Australia's biotech ambitions and America's startup culture — but he says the sector needs a Canva moment to truly take flight.

Number 8 Bio co-founder and CEO Tom Williams is betting that farmers will choose his methane-busting feed over a growing pack of competitors.

The Main Sequence-backed startup plans to build a unique facility here in Australia, though US incentives are also tempting, says CEO Michele Stansfield

The biotech company, one of the largest on the ASX, saw its share price drop despite strong profit growth. Here are three reasons why.

Australia has proven capable of producing cutting-edge startups. The challenge is keeping them here.

With its biggest revenue driver in weight loss drugs like Ozempic facing uncertainty, Eucalyptus is expanding into men's longevity. But its offering isn’t cheap.

NeoGenix Biosciences is helping infertile couples find healthy sperm. In a world-first, the technology has already seen some impressive results — including a baby.